Australia markets close in 1 hour 12 minutes

Ceapro Inc. (CRPOF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.43000.0000 (0.00%)
At close: 01:42PM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.4300
Open0.4300
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.4300 - 0.4300
52-week range0.3850 - 0.7270
Volume3,000
Avg. volume10,940
Market cap33.552M
Beta (5Y monthly)1.47
PE ratio (TTM)26.88
EPS (TTM)0.0160
Earnings date20 Apr 2022 - 25 Apr 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Ceapro Inc. to Present at the Virtual Investor 2022 Top Picks Conference

    Live video webcast presentation on Thursday, January 27th at 3:00 PM ETEDMONTON, Alberta, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that Gilles Gagnon, President and Chief Executive Officer of Ceapro will present at the Virtual Investor 2022 Top Picks Conference on Thursday,

  • Simply Wall St.

    Ceapro's (CVE:CZO) Returns On Capital Not Reflecting Well On The Business

    Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...

  • GlobeNewswire

    Ceapro Inc. Announces R&D Funding to Support PGX Technology Project

    – PGX Technology further recognized as a disruptive technology – Additional support paves the way for the manufacturing of pharmaceutical-grade yeast beta glucan (YBG) EDMONTON, Alberta, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced they are receiving advisory services and up to